API
< Back to all clusters
[HEALTH] · Brazil · 2 sources

started · updated

Oncology leads pharmaceutical clinical research in Brazil

A new census conducted by Sindusfarma in partnership with Datafolha reveals that oncology is the primary focus of pharmaceutical clinical studies in Brazil, accounting for 17.8% of researched areas. Other significant areas include metabolic and endocrine diseases (15%), autoimmune and inflammatory diseases (14.9%), and the central nervous system (13.7%).

Looking ahead, 65% of companies intend to increase research investments over the next five years. Oncology remains the top priority for 26% of these firms, followed by the central nervous system (25%) and rare diseases (22%). This focus is critical as the National Cancer Institute (Inca) estimates 781,000 new cancer cases annually in Brazil between 2026 and 2028.

To support this scientific landscape, the Brazilian Ministry of Health is developing the National Registry of Clinical Research Centers (CNCPC). Coordinated by the Secretariat of Science, Technology, and Health Innovation, this initiative aims to map the infrastructure, technical competencies, and territorial reach of both public and private research centers. The registry is designed to support public policy, reduce regional inequalities, and accelerate the development of medicines and vaccines for the Unified Health System (SUS).

Entities

Brazil · Ministry of Health · National Cancer Institute · Sindusfarma · Unified Health System